RxDoctor Payments Data

Woody Jenkins, MD

Internal Medicine · Stillwater, OKNPI 1639156672

Payments from drug & device makers

$1,781in general payments, 2019–2025

Across 117 payments — averaging $15.22 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Lilly USA, LLC$209
  • Pfizer$202
  • Amarin Pharma, Inc.$180
  • AstraZeneca$178
  • AbbVie$154
  • Abbott$153
  • plus $705 from 19 others

What the payments were for

  • Food & beverage$1,775100%
  • Education$60%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

19
20
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

How this compares

$1,781 in reported general payments places this provider in the 75th percentile of 840 internal medicine providers in Oklahoma.

See all internal medicine providers in Oklahoma

Medicare billing

Part B allowed, 2024
$271,826
Medicare patients
747
Services billed
3,745

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
EliquisApixaban138$112,554
JardianceEmpagliflozin60$39,502
FarxigaDapagliflozin Propanediol33$24,317
XareltoRivaroxaban22$18,952
JanuviaSitagliptin Phosphate11$17,386
Toujeo SolostarInsulin Glargine,hum.Rec.Anlog17$15,723
OzempicSemaglutide16$14,936
EntrestoSacubitril/Valsartan16$12,698
Xtampza ErOxycodone Myristate13$12,137
Lantus SolostarInsulin Glargine,hum.Rec.Anlog75$12,081
Trelegy ElliptaFluticasone/Umeclidin/Vilanter19$11,717
Dexlansoprazole DrDexlansoprazole13$7,819
Basaglar Kwikpen U-100Insulin Glargine,hum.Rec.Anlog23$7,206
Breo ElliptaFluticasone/Vilanterol12$6,789
Atorvastatin Calcium465$6,481

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
PfizerEliquis, Premarin$202$116,371158 claims
Boehringer IngelheimJardiance$54$39,50260 claims
AstraZenecaFarxiga, Symbicort$178$30,43252 claims
MerckJanuvia, Janumet Xr, Dulera$27$27,22433 claims
GSKTrelegy Ellipta, Breo Ellipta, Anoro Ellipta$77$23,55042 claims
Johnson & JohnsonXarelto$24$18,95222 claims
Novo NordiskOzempic$24$14,93616 claims
NovartisEntresto$142$12,69816 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 75th percentile of 840 internal medicine providers in Oklahoma.

Other internal medicine in Stillwater

See the full list for Oklahoma

Where these figures come from

Is this you, or does something look wrong? →